About 5 results found for searched term "Cetuximab" (0.327 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6103 | Cetuximab | EGFR/HER2 |
| C225；Erbitux | ||
| Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). | ||
| M24965 | Cetuximab sarotalocan | EGFR/HER2 |
| RM-1929; Cetuximab-IRDye-700DX | ||
| Cetuximab sarotalocan (Cetuximab-IRDye-700DX) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research. | ||
| M24595 | Patritumab | EGFR/HER2 |
| Human Anti-ERBB3 Recombinant Antibody | ||
| Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab , potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. | ||
| M49472 | LY3164530 | EGFR/HER2 |
| LY-3164530 | ||
| LY3164530 is a bispecific antibody targeting c-MET/EGFR that fuses scFv (cetuximab) to the N-terminal end of the heavy chain of emibetuzumab, resulting in a 2+2 symmetric bis-antibody, which is of the IgG4 subtype, and has little to no associated effects such as ADCC. | ||
| M49949 | LDN-211904 oxalate | Ephrin Receptor |
| LDN-211904 oxalate is a potent and selective EphB3 inhibitor with an IC50 of 0.079 µM.LDN-211904 oxalate showed good metabolic stability in mouse liver microsomes.LDN-211904 oxalate was shown to be effective in inhibiting STAT3-activated CSC stemness in combination with cetuximab. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
